Delgocitinib Cream Improves Chronic Hand Eczema in Second Phase 3 Trial
Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor.
Delgocitinib cream is a topical pan-Janus kinase (JAK) inhibitor.
The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success.
The sBLA is supported by data from the phase 3 PRIME2 and PRIME trials that assessed dupilumab in patients 18 years of age and older with prurigo nodularis.
The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.